INHIBITION OF GLUTAMINYL CYCLASE ENHANCES INACTIVATION OF CCL2: A POTENTIAL THERAPY FOR CARDIOVASCULAR DISEASE

被引：0
|
作者：
Cynis, H. [1 ]
Hoffmann, T. [2 ]
Schilling, S. [1 ]
Demuth, H-U
机构：
[1] Probiodrug AG, Enzymol, Halle, Germany
[2] Probiodrug AG, In Vitro Pharmacol, Halle, Germany
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2009年 / 10卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Glutaminyl cyclase, a degenerated aminopeptidase - a new causative target in Alzheimer's disease therapy
    Demuth, H. U.
    Cynis, H.
    Ulrich, H.
    Stephan, S.
    FEBS JOURNAL, 2009, 276 : 77 - 78
  • [22] Evaluation of CCL2 as a potential biomarker of pulmonary vascular disease in limited cutaneous systemic sclerosis
    Carulli, MT
    Ong, VH
    Abraham, DJ
    Coghlan, GJ
    Black, CM
    Denton, CP
    RHEUMATOLOGY, 2005, 44 : I128 - I128
  • [23] Reduction in Disease Progression by Inhibition of Transforming Growth Factor α-CCL2 Signaling in Experimental Posttraumatic Osteoarthritis
    Appleton, C. Thomas G.
    Usmani, Shirine E.
    Pest, Michael A.
    Pitelka, Vasek
    Mort, John S.
    Beier, Frank
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (10) : 2691 - 2701
  • [24] Association of CCL5 rs2107538, and CCL2 rs3760396 Gene Polymorphisms with the Risk of Cardiovascular Disease
    Mohtavinejad, Naser
    Nakhaee, Alireza
    Harati, Honey
    Gholipour, Nazila
    Mahmoodzade, Yavar
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2021, 50 (07) : 1436 - 1444
  • [25] Il-10 enhances CCL2 release and chemotaxis induced by CCL16 in human monocytes
    Musso, T
    Cappello, P
    Stornello, S
    Ravarino, D
    Caorsi, C
    Otero, K
    Novelli, F
    Badolato, R
    Giovarelli, M
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2005, 18 (02) : 339 - 349
  • [26] Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice
    Cynis, Holger
    Kehlen, Astrid
    Haegele, Monique
    Hoffmann, Torsten
    Heiser, Ulrich
    Fujii, Masato
    Shibazaki, Yuichiro
    Yoneyama, Hiroyuki
    Schilling, Stephan
    Demuth, Hans-Ulrich
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2013, 94 (03) : 217 - 225
  • [27] Evaluation of CCL2 as a potential biomarker of pulmonary vascular disease in limited cutaneous systemic sclerosis.
    Carulli, MT
    Ong, VH
    Abraham, DJ
    Coghlan, G
    Black, CM
    Denton, CP
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S425 - S426
  • [28] CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study
    Tsaur, Igor
    Noack, Anika
    Makarevic, Jasmina
    Oppermann, Elsie
    Waaga-Gasser, Ana Maria
    Gasser, Martin
    Borgmann, Hendrik
    Huesch, Tanja
    Gust, Kilian M.
    Reiter, Michael
    Schilling, David
    Bartsch, Georg
    Haferkamp, Axel
    Blaheta, Roman A.
    CANCER RESEARCH AND TREATMENT, 2015, 47 (02): : 306 - 312
  • [29] Potential Role of Macrophage Phenotypes and CCL2 in the Pathogenesis of Takayasu Arteritis
    Kong, Xiufang
    Xu, Ming
    Cui, Xiaomeng
    Ma, Lingying
    Cheng, Huiyong
    Hou, Jun
    Sun, Xiaoning
    Ma, Lili
    Jiang, Lindi
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [30] Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
    Zhu, Xinmei
    Fujita, Mitsugu
    Snyder, Linda A.
    Okada, Hideho
    JOURNAL OF NEURO-ONCOLOGY, 2011, 104 (01) : 83 - 92
12345